Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Dose intensive regimen of CK0804 tregs in myelofibrosis

View Full Paper
Ask AI
Bookmark
Share

Authors

LMLucia MasárováThe University of Texas MD Anderson Cancer CenterTKTapan KadiaThe University of Texas MD Anderson Cancer CenterGMGuillermo Montalban‐BravoThe University of Texas MD Anderson Cancer Center

Discussion

Loading...

Member takes

Implication

Expansion cohort shows CK0804 Tregs improve symptom burden and mitigate adverse events in myelofibrosis patients on ruxolitinib.

Key Points

  • Adverse events were absent in 4 patients receiving dose intensive CK0804 Tregs, indicating good safety.
  • Symptom burden dropped by 49% in responders at 12 months after CK0804 Treg therapy compared to a rise in non-responders.
  • Analysis assessed treatment impact across fluctuating hemoglobin and stable platelet counts during the study.
  • Cytokines including IL-6 decreased significantly in responders, highlighting the immune system's positive alteration.

Cite This Study

Masárová et al. (2025) studied this question.

synapsesocial.com/papers/69362f6c4fa91c937236df85https://doi.org/10.1182/blood-2025-5602
View Full Paper
Ask AI
Bookmark
Share